Psoriasis and the metabolic syndrome

Dermatologic Therapy

Volumn 23, Issue 2, 2010, Pages 137-143

  Alsufyani, Mohammed Ahmed ^a   Golant, Alexandra K ^b   Lebwohl, Mark ^b  

^a The General Directorate of Armed Forces Health Services   (Saudi Arabia)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Comorbidities; Metabolic syndrome; Psoriasis

Indexed keywords

ABDOMINAL OBESITY; ALCOHOL CONSUMPTION; CARDIOVASCULAR DISEASE; COMORBIDITY; DISEASE ASSOCIATION; DYSLIPIDEMIA; HIGH RISK PATIENT; HUMAN; HYPERTENSION; INSULIN RESISTANCE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PSORIASIS; REVIEW; SMOKING; STROKE; T LYMPHOCYTE;

ADULT; COMORBIDITY; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; OBESITY, ABDOMINAL; PSORIASIS; SEDENTARY LIFESTYLE; STROKE;

EID: 77950134115     PISSN: 13960296     EISSN: 15298019     Source Type: Journal    
DOI: 10.1111/j.1529-8019.2010.01307.x     Document Type: Review

References (61)

1. Nevitt GJ, Hutchinson PE. Psoriasis in the community: prevalence, severity and patients beliefs and attitudes towards the disease. Br J Dermatol 1996 : 135 : 533 537.
2. Gottlieb AB, Chao C, Dann F. Psoriasis comorbidities. J Dermatolog Treat 2008 : 19 : 5 21.
3. Nickoloff BJ, Nestle FO. Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities. J Clin Inves 2004 : 113 : 1664 1675.
4. Schlaak JF, Buslau M, Jochum W, et al. T cells involved in psoriasis vulgaris belong to the Th1 subset. J Invest Derm 1994 : 102 : 145 149.
5. Krueger JG. The immunologic basis for the treatment of psoriasis with new biologic agents. J Am Acad Dermato 2002 : 46 : 1 23.
6. Fitch E, Harper E, Skorcheva I, Kurtz SE, Blauvelt A. Pathophysiology of psoriasis: recent advances on IL-23 and Th17 cytokines. Curr Rheumatol Rep 2007 : 9 : 461 467.
7. Winterfield LS, Menter A, Gordon K, Gottlieb A. Psoriasis treatment: current and emerging directed therapies. Ann Rheum Dis 2005 : 64 : ii87 ii90 discussion ii91-ii92.
8. Yosipovitch G, DeVore A, Dawn A. Obesity and the skin: skin physiology and skin manifestations of obesity. J Am Acad Dermatol 2007 : 56 : 901 916.
9. Sterry W, Strober BE, Menter A International Psoriasis Council. Obesity in psoriasis: the metabolic, clinical and therapeutic implications. Report of an interdisciplinary conference and review. Br J Dermatol 2007 : 157 : 649 655.
10. Kimball AB, Jacobson C, Weiss S, Vreeland MG, Wu Y. The psychological burden of psoriasis. Am J Clin Dermatol 2005 : 6 : 383 392.
11. Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of myocardial infarction in patients with psoriasis. JAMA 2006 : 296 : 1735 1741.
12. Sommer DM, Jenisch S, Suchan M, Christophers E, Weichental M. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch Dermatol Res 2006 : 298 : 321 328.
13. Cohen AD, Gilutz H, Henkin Y, et al. Psoriasis and the metabolic syndrome. Acta Derm Venereol 2007 : 87 : 506 509.
14. National Institutes of Health. Third Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Executive Summary. NIH Publication No. 01-3670, 2001.
15. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005 : 365 : 1415 1428.
16. Ford ES. Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: A summary of the evidence. Diabetes Care 2005 : 28 : 1769 1778.
17. Laaksonen DE, Lakka HM, Niskanen LK, Kaplan GA, Salonen JT, Lakka TA. Metabolic syndrome and development of diabetes mellitus: Application and validation of recently suggested definitions of the metabolic syndrome in a prospective cohort study. Am J Epidemiol 2002 : 156 : 1070 1077.
18. Isomaa B, Almgren P, Tuomi T, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001 : 24 : 683 689.
19. Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB, Gelfand JM. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermtol 2006 : 55 : 829 835.
20. Herron MD, Hinckley M, Hoffman MS, et al. The impact of obesity and smoking on psoriasis presentation and management. Arch Dermatol 2005 : 141 : 1527 1534.
21. Fortes C, Mastroeni S, Leffondre K, et al. Relationship between smoking and the clinical severity of psoriasis. Arch Dermatol 2005 : 141 : 1580 1584.
22. Mallbris L, Granath F, Hamsten A, Stahle M. Psoriasis is associated with lipid abnormalities at the onset of skin disease. J Am Acad Dermatol 2006 : 54 : 614 621.
23. Naldi L, Chatenoud L, Linder D, et al. Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: results from an Italian case-control study. J Invest Dermatol 2005 : 125 : 61 67.
24. Rocha-Pereira P, Santos-Silva A, Rebelo I, Figueiredo A, Quintanilha A, Teixeira F. Dyslipidemia and oxidative stress in mild and in severe psoriasis as a risk for cardiovascular disease. Clin Chim Acta 2001 : 303 : 33 39.
25. Uyanik BS, Ari Z, Onur E, Gündüz K, Tanülkü S, Durkan K. Serum lipids and apolipoproteins in patients with psoriasis. Clin Chem Lab Med 2002 : 40 : 65 68.
26. Piskin S, Gurkok F, Ekuklu G, Senol M. Serum lipid levels in psoriasis. Yonsei Med J 2003 : 44 : 24 26.
27. Pietrzak A, Lecewicz-Torun B. Activity of serum lipase [EC 3.1.1.3] and the diversity of serum lipid profile in psoriasis. Med Sci Monit 2002 : 8 : CR9 CR13.
28. Seishima M, Seishima M, Mori S, Noma A. Serum lipid and apolipoprotein levels in patients with psoriasis. Br J Dermatol 1994 : 130 : 738 742.
29. Qureshi AA, Choi HK, Setty AR, Curhan GC. Psoriasis and the risk of diabetes and hypertension: a prospective study of US female nurses. Arch Dermatol 2009 : 145 : 379 382.
30. Brauchli YB, Jick SS, Meier CR. Psoriasis and the risk of incident diabetes mellitus: a population-based study. Br J Dermatol 2008 : 159 : 1331 1337.
31. Tam LS, Tomlinson B, Chu TT, et al. Cardiovascular risk profile of patients with psoriatic arthritis compared to controls - the role of inflammation. Rheumatology (Oxford) 2008 : 47 : 718 723.
32. Gisondi P, Tessari G, Conti A, et al. Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case-control study. Br J Dermatol 2007 : 157 : 68 73.
33. Cohen AD, Sherf M, Vidavsky L, Vardy DA, Shapiro K, Meyerovitch J. Association between psoriasis and the metabolic syndrome. Dermatology 2008 : 216 : 152 155.
34. Brauchli YB, Jick SS, Miret M, Meier CR. Psoriasis and risk of incident myocardial infarction, stroke or transient ischemic attack: an inception cohort study with a nested case-control analysis. Br J Dermatol 2009 : 160 : 1048 1056.
35. Gelfand JM, Dommasch ED, Shin DB, et al. The risk of stroke in patients with psoriasis. J Invest Dermatol 2009 : 129 : 2411 2418.
36. Kaye JA, Li L, Jick SS. Incidence of risk factors for myocardial infarction and other vascular diseases in patients with psoriasis. Br J Dermatol 2008 : 159 : 895 902.
37. Libby P. Inflammation and cardiovascular disease mechanisms. Am J Clin Nutr 2006 : 83 : 456S 460S.
38. Willerson JT, Ridker PM. Inflammation as a cardiovascular risk factor. Circulation 2004 : 109 : II2 II10.
39. Ludwig RJ, Herzog C, Rostock A, et al. Psoriasis: a possible risk factor for development of coronary artery calcification. Br J Dermatol 2007 : 271 : 271 276.
40. Bijlan D, Situm M, Kostovic K, Batinac T, Mastisic D. Acute phase proteins in psoriasis. Coll Antropol 2009 : 33 : 83 86.
41. Chen YJ, Shen JL, Wu CY, Chang YT, Chen CM, Lee FY. Elevated plasma osteopontin level is associated with occurrence of psoriasis and is an unfavorable cardiovascular risk factor in patients with psoriasis. J Am Acad Dermatol 2009 : 60 : 225 230.
42. Cerman AA, Bozkurt S, Sav A, Tulunay A, Elbasi MO, Ergun T. Serum leptin levels, skin leptin and leptin receptor expression in psoriasis. Br J Dermatol 2008 : 159 : 820 826.
43. Chen YJ, Wu CY, Shen JL, et al. Psoriasis independently associated with hyperleptinemia contributing to metabolic syndrome. Arch Dermatol 2008 : 144 : 1571 1575.
44. Kaur S, Zilmer K, Kairane C, Kals M, Zilmer M. Clear differences in adiponectin level and glutathione redox status revealed in obese and normal-weight patients with psoriasis. Br J Dermatol 2008 : 159 : 1364 1367.
45. Shibata S, Saeki H, Tada Y, Karakawa M, Komine M, Tamaki K. Serum high molecular weight adiponectin levels are decreased in psoriasis patients. J Dermatol Sci 2009 : 55 : 62 63.
46. Takahashi H, Tsuji H, Takahashi I, Hashimoto Y, Ishida-Yamamoto A, Iizuka H. Plasma adiponectin and leptin levels in Japanese patients with psoriasis. Br J Dermatol 2008 : 159 : 1207 1208.
47. Johnston A, Arnadottir S, Gudjonsson JE, et al. Obesity in psoriasis: leptin and resistin as mediators of cutaneous inflammation. Br J Dermatol 2008 : 159 : 342 350.
48. Shetty GK, Economides PA, Horton ES, Mantzoros CS, Veves A. Circulating adiponectin and resistin levels in relation to metabolic factors, inflammatory markers, and vascular reactivity in diabetic patients and subjects at risk for diabetes. Diabetes Care 2004 : 27 : 2450 2457.
49. Eldibany MM, Caprini JA. Hyperhomocysteinemia and thrombosis: an overview. Arch Pathol Lab Med 2007 : 131 : 872 884
50. Gisondi P, Girolomoni G. Psoriasis and atherothrombotic diseases: disease-specific and non-disease-specific risk factors. Semin Thromb Hemost 2009 : 35 : 313 324.
51. Malerba M, Gisondi P, Radaeli A, Sala R, Calzavara Pinton PG, Girolomoni G. Plasma homocysteine and folate levels in patients with chronic plaque psoriasis. Br J Dermatol 2006 : 155 : 1165 1169.
52. Malik S, Wong ND, Franklin S, Pio J, Fairchild C, Chen R. Cardiovascular disease in U.S. patients with metabolic syndrome, diabetes, and elevated C-reactive protein. Diabetes Care 2005 : 28 : 690 693.
53. Chodorowska G, Wojnowska D, Juszkiewicz-Borowiec M. C-reactive protein and alpha2-macroglobulin plasma activity in medium-severe and severe psoriasis. J Eur Acad Dermatol Venereol 2004 : 18 : 180 183.
54. Dauden E, Misery L, Christophers E, Molta C, Bolge S, Boggs R. Moderate to severe psoriatic patients are more likely to smoke, less likely to exercise regularly and less likely to maintain a healthy diet than non-psoriatic controls. Poster presented at the 17th Congress of the European Academy of Dermatology and Venereology 2008 Sep 17-20; Paris, France.
55. Wakkee M, Herings RM, Nijsten T. Psoriasis may not be an independent risk factor for acute ischemic heart disease hospitalizations: Result of a large population-based Dutch cohort. J Invest Dermatol 2009 Oct 8 [Epub ahead of print M, Meijer W, Neumann HA, Herings RM, Nijsten T. Psoriasis may not be an independent predictor for the use of cardiovascular and anti-diabetic drugs: a 5-year prevalence study. Acta Dermato-Venereologica 2009 : 89 : 476 483.
56. Prodanovich S, Ma F, Taylor JR, Pezon C, Fasihi T, Kirsner RS. Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis. J Am Acad Dermatol 2005 : 52 : 262 267.
57. Dixon WG, Watson KD, Lunt M, Hyrich KL, Silmen AJ, Symmons DP. Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-TNF alpha therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2007 : 56 : 2905 2912.
58. Jacobsson LT, Turesson C, Gulfe A, et al. Treatment with TNF blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. J Rheumatol 2005 : 32 : 1213 1218.
59. Jacobsson LT, Turesson C, Nilsson JA, et al. Treatment with TNF blockers and mortality risk in patients with rheumatoid arthritis. Ann Rheum Dis 2007 : 66 : 670 675.
60. Strober B, Teller C, Yamauchi P, et al. Effects of etanercept on C-reactive protein levels in psoriasis and psoriatic arthritis. Br J Dermatol 2008 : 159 : 322 330.
61. Marra M, Campanati A, Testa R, et al. Effect of etanercept on insulin sensitivity in nine patients with psoriasis. Int J Immunopathol Pharmacol 2007 : 20 : 731 736.